Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Objectives: This review investigates characteristics of implemented adaptive design clinical trials and provides examples of regulatory experience with such trials. Design: Review of adaptive design clinical trials in EMBASE, PubMed, Cochrane Registry of Controlled Clinical Trials, Web of Science and ClinicalTrials.gov. Phase I and seamless Phase I/II trials were excluded. Variables extracted from trials included basic study characteristics, adaptive design features, size and use of independent data monitoring committees (DMCs) and blinded interim analyses. We also examined use of the adaptive trials in new drug submissions to the Food and Drug Administration (FDA) and European Medicines Agency (EMA) and recorded regulators’ experiences with adaptive designs. Results: 142 studies met inclusion criteria. There has been a recent growth in publicly reported use of adaptive designs among researchers around the world. The most frequently appearing types of adaptations were seamless Phase II/III (57%), group sequential (21%), biomarker adaptive (20%), and adaptive dose-finding designs (16%). About one-third (32%) of trials reported an independent DMC, while 6% reported blinded interim analysis. We found that 9% of adaptive trials were used for FDA product approval consideration, and 12% were used for EMA product approval consideration. International regulators had mixed experiences with adaptive trials. Many product applications with adaptive trials had extensive correspondence between drug sponsors and regulators regarding the adaptive designs, in some cases with regulators requiring revisions or alterations to research designs. Conclusions: Wider use of adaptive designs will necessitate new drug application sponsors to engage with regulatory scientists during planning and conduct of the trials. Investigators need to more consistently report protections intended to preserve confidentiality and minimise potential operational bias during interim analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the Gold Standard — Lessons from the History of RCTs
Bothwell, L. E., Greene, J. A., Podolsky, S. H., & Jones, D. S. (2016) · New England Journal of Medicine · doi:10.1056/nejmms1604593 · Cited by 664 · cited 1×
“Yet, modern RCTs can demand substantial time and resources.(1) Adaptive designs have been developed as an alternative to traditional RCT design.”
Self-citationAdaptive design methods in clinical trials–a review
Chow, S.-C., & Chang, M. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-11 · Cited by 482
Adaptive trial designs: a review of barriers and opportunities
Kairalla, J. A., Coffey, C. S., Thomann, M. A., & Muller, K. E. (2012) · Trials · doi:10.1186/1745-6215-13-145 · Cited by 249
Adaptive designs undertaken in clinical research: a review of registered clinical trials
Hatfield, I., Allison, A., Flight, L., Julious, S. A., & Dimairo, M. (2016) · Trials · doi:10.1186/s13063-016-1273-9 · Cited by 107
Cited by
Clinical utility of polygenic risk scores for coronary artery disease
Klarin, D., & Natarajan, P. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00638-w · Cited by 152
Phase II Trials in Drug Development and Adaptive Trial Design
Van Norman, G. A. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.02.005 · Cited by 133
Dimairo, M., Pallmann, P., Wason, J., Todd, S., Jaki, T., Julious, S. A., Mander, A. P., Weir, C. J., Koenig, F., Walton, M. K., et al. (2020) · Trials · doi:10.1186/s13063-020-04334-x · Cited by 58
“In summary, ADs are used in a relatively low proportion of trials, although their use is steadily increasing in both the public and private sectors [114 – 116], and they are frequently considered at the design stage [27].”
BackgroundBricker, J., Miao, Z., Mull, K., Santiago-Torres, M., & Vock, D. M. (2023) · Journal of Medical Internet Research · doi:10.2196/43629 · Cited by 22
Metadata
- Authors
- Bothwell, L. E., Avorn, J., Khan, N. F., & Kesselheim, A. S.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2018-02
- Volume
- 8
- Issue
- 2
- Pages
- e018320
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W2793703203
- Cited by
- 196
- References
- 4
- FWCI
- 15.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov. https://app.cochat.ai/papers/10.1136/bmjopen-2017-018320
- The paper
- Bothwell, L. E., Avorn, J., Khan, N. F., & Kesselheim, A. S. (2018). Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov. BMJ Open. https://doi.org/10.1136/bmjopen-2017-018320
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.